Navigation Links
New Treatment May Boost Survival in Advanced Lung Cancer Cases
Date:11/9/2011

By Amanda Gardner
HealthDay Reporter

WEDNESDAY, Nov. 9 (HealthDay News) -- For the first time, "epigenetic" therapy has shown promise in patients with solid tumors, in this case non-small cell lung cancers.

Of 45 patients in a trial of this experimental treatment, two had a complete response to therapy, one had a partial response and one is still alive more than four years after starting therapy.

"It's not a home run, but this trial has opened the door for further research into epigenetic therapy," said Dr. Stephen Baylin, co-author of the study appearing online Nov. 9 and in the December issue of Cancer Discovery.

Other experts were both hopeful and cautious.

"The exciting part of this study is that they're using therapies that have really never worked in solid tumors, and this is one of the first studies to show that these types of therapies may work in solid tumors, and more specifically in lung cancer," said Dr. Benjamin Levy, director of thoracic medical oncology at Beth Israel Medical Center in New York City. "But until we get this validated in larger studies, it's unclear where this type of therapy in terms of altering epigenetic regulation is going to have a place in lung cancer."

"You have to view this as extremely preliminary. It is a small study with what one could almost argue are anecdotal-type findings," said Dr. Edward Kim, chief of head and neck medical oncology at MD Anderson Cancer Center in Houston. "There's not a lot I could apply to my patients, though the results are intriguing."

Some 80 percent of lung cancers are non-small cell lung cancers, which have few effective treatments and, consequently, a dire prognosis.

Epigenetic therapy involves targeting the proteins wrapped around DNA, which regulate changes in actual gene expression. Unlike genetic mutations, epigenetic abnormalities can be reversed, explained Levy.

This phase 1/2 trial involved 45 patients with metastatic non-small cell lung cancer who had tried and failed multiple other therapies.

One of the drugs used in the study, azacitidine, had been tested on different cancers decades ago but was deemed too toxic to use. It's now approved in much lower doses for patients with myelodysplastic syndrome, which can be a precursor to leukemia.

These researchers also used low doses of azacitidine, combined with a newer drug, etinostat. Each drug targets a different epigenetic pathway.

With this combination, patients lived an average of 6.4 months, which is about two months longer than what otherwise would have been expected, said Levy.

Two patients saw "a virtually complete response," said Baylin, who is a professor of oncology and deputy director of the Kimmel Cancer Center at Johns Hopkins University in Baltimore. One lived for three years after therapy before dying of a different type of lung tumor. The other is still alive three years after joining the trial and "his original disease metastasis to his liver has not come back."

After completing the epigenetic therapy, four patients went on to respond to other therapies. "This has set up the possibility that we're priming patients so that subsequent therapies work better," Baylin said, cautioning that this is not yet proven.

Importantly, side effects were "milder than typical chemotherapy," Baylin said. "No patient had to come off of the trial because of toxicity."

The researchers were also able to identify biomarkers that may be able to predict which patients will respond well to this epigenetic therapy.

"This doesn't work in a majority of patients, but there is a small subset that really derive exceptional benefits from this approach," said Rudin. The challenge now is to identify these patients, he added.

Although the study suggested an association between the therapy and increased survival, it does not prove a cause-and-effect.

More information

The U.S. National Cancer Institute has more on non-small-cell lung cancer.

SOURCES: Stephen B. Baylin, M.D., professor, oncology, and deputy director, Kimmel Cancer Center, Johns Hopkins University, Baltimore; Edward Kim, M.D., chief, section of head and neck medical oncology, MD Anderson Cancer Center, Houston; Benjamin Levy, M.D., director, thoracic medical oncology, Beth Israel Medical Center, New York City; Nov. 9, 2011, Cancer Discovery, online


'/>"/>
Copyright©2010 ScoutNews,LLC.
All rights reserved  

Related medicine news :

1. In a childhood cancer, basic biology offers clues to better treatments
2. New artemisinin-based treatment against malaria promising
3. New Bypass Surgery for Stroke Riskier Than Drug Treatment
4. Northern Ireland company makes major breakthrough in cancer treatment
5. Major project to implement new treatments to boost kala-azar elimination strategies
6. Study identifies factors linked with better medication response for treatment of juvenile arthritis
7. More Targeted Treatments Key to Progress in War on Cancer: Report
8. Wayne State therapeutic marijuana use study could impact state policies, guide treatment
9. Gene therapy shows promise as hemophilia treatment in animal studies
10. Researchers reveal potential treatment for sickle cell disease
11. ASU leads $5 million NIH-sponsored research initiative to advance diabetes care and treatment
Post Your Comments:
*Name:
*Comment:
*Email:
Related Image:
New Treatment May Boost Survival in Advanced Lung Cancer Cases
(Date:4/29/2016)... ... April 29, 2016 , ... A new study by a ... diaphragmatic hernia have better survival rates if surgery is performed early. Approximately one ... the diaphragm fails to form completely, letting abdominal organs into the chest cavity ...
(Date:4/29/2016)... ... 29, 2016 , ... The Wharton School of the ... Prize of the 2016 Wharton Business Plan Competition —as well as the ... and the Committee Award for Most ‘Wow Factor,’ making them the first team ...
(Date:4/29/2016)... ... April 29, 2016 , ... ... announces the Gyrociser, an exercise invention which aids in proper muscle development. , ... Cooper, CEO and Creative Director of World Patent Marketing. "Globalization has threatened the ...
(Date:4/29/2016)... ... 2016 , ... Melanoma is the deadliest type of skin cancer. Although only about 1 percent ... cancer deaths. More than 10,000 people are expected to die of melanoma this year. The ... the one of the most commonly diagnosed cancers in young women. A recent breakthrough in ...
(Date:4/29/2016)... ... ... City based oral and maxillofacial surgeon Dr. Majid Jamali is an expert in ... apnea. Dr. Jamali is proud to offer this permanent solution to patients who suffer from ... bones. This surgery is performed to correct the alignment of the jaw. It is beneficial ...
Breaking Medicine News(10 mins):
(Date:4/27/2016)... Shire plc (LSE: SHP, NASDAQ: ... Financial Officer, will present at the Deutsche Bank 41st Annual ... on Wednesday, May 04, 2016, 10:00 am EDT (15:00 BST). ... the Presentations and Webcasts section of Shire,s Investor website at ... be available on this same website for approximately 90 days. ...
(Date:4/27/2016)... 2016 Global  urinalysis market ... by 2022, according to a new report by ... http://photos.prnewswire.com/prnh/20150105/723757 ) , Automation ... and accuracy delivered by the new generation urinalysis ... urinalysis instruments and consumables. For instance, the automatic ...
(Date:4/26/2016)... April 26, 2016 Diplomat Pharmacy, Inc. (NYSE: ... Jennifer Hagerman , Pharm D., to Vice President of ... at Diplomat, Hagerman will continue to lead and oversee ... delivers custom education and training to Diplomat employees and ... industry. Diplomat University also houses the quality assurance department, ...
Breaking Medicine Technology: